Acute Asthma ExacerbationsAERMISNCT06652542
Asthma Exacerbations & Respiratory Management International Survey
An observational study of Acute Asthma Exacerbations, run by Assiut University at 2 sites in 2 countries.
Trial summary
Asthma is a chronic health condition that affects 300 million humans worldwide and is thought to cause around 1.000 deaths per day. It's estimated that asthma leads to a significant increase in disability adjusted life years (DALYs). Read more about this study
- Who is it for?
- Ages 23 years and older
- Conditions the study is for
- Acute Asthma Exacerbations
- How many people
- 93 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 20 Feb 2024to 20 Feb 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 23 years and older
- All sexes
- Adult, Older adult
Study population: Pulmonologists, internists, paediatricians, and intensivists at primary, secondary, or tertiary health care facility, from different countries and geographic territories, with varying years of experience and academic backgrounds
Who may be able to join
- All practicing physician who may encounter patients with asthma during their clinical practice are invited to participate.
Who cannot join
- Non-practicing undergraduate medical students
Trial locations and contacts
2 sites in 2 countries.
2 sites in 2 countries
Spain1 site
International Association of Noninvasive Mechanical Ventilation
Murcia
About this study
Official title: Asthma Exacerbations & Respiratory Management: An International Online Survey Endorsed by the International Association of Non-invasive Ventilation & International College of Experts
Asthma is a chronic health condition that affects 300 million humans worldwide and is thought to cause around 1.000 deaths per day. It's estimated that asthma leads to a significant increase in disability adjusted life years (DALYs). Acute asthma exacerbations affect 25-56% of patients with asthma and represent 8% of intensive care unit (ICU) admissions. Acute asthma exacerbations continue to burden different health systems, particularly emergency units and intensive care units, despite vast advances in pharmacological treatment of asthma, development of evidence-based clinical practice guidelines to improve care of asthma.
This alarming situation indicates non-consensus regarding the best approach for managing acute exacerbations of asthma. Despite that variations in clinical practice regarding diagnosis, prevention, education, long-term management and symptom control of asthma have been thoroughly studied globally, less light has been shed on divergence of physicians' approaches when encountering asthmatic patients during acute exacerbations.
Read the detailed description
Aim of the Study:
Exploring the physicians' knowledge, attitude and current clinical, pharmacological and ventilatory management practices for acute asthma exacerbations.
Methodology:
Study Design:
The survey is intended to be a cross-sectional survey study.
Time Period:
February 2024-February 2025.
Study Settings:
Respondents are to be recruited by the authors, who are to distribute the online survey to targeted colleagues within the medical institutions the authors are affiliated to, and through different national and international scientific societies of common interest in pulmonology and critical care medicine. Individual physicians are free to distribute the online questionnaire form via electronic communication through the channels they deem most appropriate.
Target Respondents:
Physicians involved in the care of adult asthmatic patients (general practitioners, family medicine doctors, internists, pulmonologists, intensivists in different medical ICUs).
Development of the Questionnaire Questions:
First, a thorough revision of existing literature related to different aspects of management of asthma exacerbations was performed. A total of 45 articles published in national and international journals -including review articles, clinical trials, editorials, and meta-analyses-discussing diagnosis, severity assessment, pharmacological and ventilatory management, as well as outcomes of acute asthma exacerbations were examined to find points of variation in clinical practice, distinguish which approaches are evidence-based, and the magnitude and the pattern of deviation from clinical practice guidelines in different countries. Then, data to be explored were organized into seven domains:
Domain 1.: Respondents' characteristics:
This includes age, geographic region, specialty, years of experience, clinical position and academic degree (if present), affiliation, as well as the level of the health care facility through which a respondent provides care to patients presenting with acute asthma exacerbations.
Domain 2.: Diagnosis of acute asthma exacerbations:
Respondents are to report whether their reliance is wholly on clinical judgement or on tools provided by certain local or international practice guidelines when it comes to identifying asthma patients in acute exacerbations and deciding upon emergency room (ER) admission or ICU referral.
Domain 3.: Pharmacological Management of Acute Asthma Exacerbations:
This domain aims to measure the respondents' knowledge about different pharmacological therapies administrated during acute asthma exacerbations, their usual practice as governed by local policies and resources, as well as their individual preferences towards certain approaches, to detect gaps between knowledge and practice. Drugs including bronchodilators, systemic steroids, antibiotics, and anti-histaminic are to be inquired about regarding frequency of use, method of administration, prescribed doses, and ideal/preferred alternatives. Use of other drugs like magnesium sulphate, theophylline, epinephrine, inhaled anesthetics and intravenous ketamine is to be verified, and respondents are asked to report their knowledge about whether the use of any of these drugs is endorsed by any clinical practice guidelines they are aware of.
Domain 4.: Oxygen therapy during acute asthma exacerbations:
This domain screens the knowledge of the respondents about indications of oxygen administration during acute asthma exacerbations, explores their attitude towards the choice of oxygen delivery system. Familiarity of respondents with the settings of high-flow nasal cannula (HFNC), barriers towards its use, as well as physicians' preferences regarding HFNC are also explored.
Domain 5.: Non-invasive ventilation (NIV) in acute asthma exacerbations:
Access to NIV, frequency of its use, the available NIV devices, and the preferred NIV mode and interfaces by a respondent are inquired about. Respondents' knowledge of the physiological rationales behind using NIV, the appropriate settings of NIV for patients presenting with acute asthma exacerbations, and how to address the main problems arising in such patients are challenged. Knowledge, attitudes and respondents' preferences towards use of sedation during NIV in critically ill asthmatics, knowledge of the best approach to deliver nebulized drugs during NIV, understanding of NIV interference with nebulization therapy, as well as individual preferences regarding the method of delivery are all explored. Barriers to the use of NIV for acute asthma exacerbations, and potential complications associated with its application are also investigated.
Domain 6.: Invasive mechanical ventilation (IMV)in acute asthma exacerbations:
Respondents are inquired about frequency of application of IMV in acute asthma exacerbations, the units where IMV is provided, their knowledge about pathophysiology of severe asthma exacerbations, the appropriate mode and settings of MV, the role of sedation and neuromuscular blockade and the respondents' attitudes and preferences towards the use of these drugs and monitoring patients whilst administration of these drugs are explored. Adjustment of ventilatory settings prior to administration of nebulized drugs and frequency of complications during IMV of acute asthma exacerbations are inquired about as well.
Domain 7.: Outcomes of acute asthma exacerbations:
Respondents' knowledge about possible predictors of prognosis of patients presenting with asthma exacerbations is assessed.
Ethical Considerations:
Ethical Considerations:
The study being academically endorsed by "The International Association of Noninvasive Mechanical Ventilation", has been subjected to evaluation by the IANIV- Bioethics Committee for Clinical Research studies evaluation, Internal Code: EST: 87/24, and was granted approval. Also, the online questionnaire form includes a disclosure in its description that clarifies that the study does not collect personal identifiable or sensitive data of the contributors or patients' data and only include information and opinions about clinical practice related to Asthma treatments. Data, e.g. age, affiliation, practice-years, are only collected for analytic purposes and are strictly treated as confidential by the authors, who assure that data will not be shared or unlawfully used. A consent statement at the start of the questionnaire states a declaration of consent and that the respondent is a medical doctor who holds at least a graduate degree in medical science. Answering "yes" leads the respondent to the first domain, while answering "no" automatically leads the respondent to the end of the form to be submitted.
The online questionnaire form includes a consent statement at the start of the questionnaire that states a declaration of consent and that the respondent is a medical doctor who holds at least a graduate degree in medical science. Answering "yes" leads the respondent to the first domain, while answering "no" automatically leads the respondent to the end of the form to be submitted.
Data Storage and Confidentiality:
Contact information, i.e. e-mail address is set to be optional. Other personal information such as age, years of experience and affiliation are to be collected for the descriptive purposes and depiction of general characteristics of the respondents providing information but are not to be unlawfully shared or distributed. Access to such information is set to be exclusively restricted to the authors of the questionnaire form. After data analysis, results will be published -maintaining respondents' anonymity- and will be available upon request.
Management of Adverse Events:
Given the commitment of the authors to respondents' confidentiality, no adverse events are expected from this study.
Statistical Analysis:
A certified epidemiologist statistician is to help with statistical analysis. Descriptive statistics will be conducted as well as relevant inferential statistics.
- Conditions
- Acute Asthma Exacerbations
- Keywords
- Asthma Exacerbations, International Survey, Attitudes and Preferences, International Association of Non-invasive Ventilation
- Medical subject headings
- Behavior
What is being measured
The primary outcome is the main question the study is designed to answer.
Physicians Knowledge & Attitudes: Diagnosis of Asthma Exacerbations
A respondent chooses from multiple choices a statement that best describes their knowledge/attitudes regarding the criteria used for diagnosis of acute asthma exacerbations (prespecified criteria derived from clinical practice guidelines or local policies rather than clinical judgement) . The number of responding physician to each statement is to be recorded.
Measured: Through study completion i.e. over an average of 1 year
Physicians' Knowledge and Attitudes: Pharmacological Management
A respondent chooses from multiple choices a statement that best describes their knowledge/attitudes regarding the use of different asthma medications (bronchodilators, steroids, sedatives, neuromuscular blockers). The number of responding physician to each statement is to be recorded.
Measured: Through study completion i.e. over an average of 1 year
Physicians Knowledge & Attitudes: Ventilatory Management
A respondent chooses from multiple choices a statement that best describes their knowledge/attitudes regarding the frequency of use of different ventilatory support methods (oxygen therapy, high-velocity nasal insufflation (HVNI), noninvasive ventilation (NIV), invasive mechanical ventilation (IMV)) and the appropriate settings. Physicians' awareness about expected adverse events of each modality is tested. The number of responding physician to each statement is to be recorded.
Measured: Through study completion i.e. over an average of 1 year
Secondary outcomes (1)
Physicians' Knowledge: Prognosis of Acute Asthma Exacerbations
A respondent chooses from multiple choices the predictors they think are predictors of poor asthma outcomes, according to their current state of knowledge. The number of responding physician to each statement is to be recorded.
Measured: Through study completion i.e. over an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2024
- Study start20 Feb 2024
- Primary completion20 Feb 2025
- Study completion20 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (12)Papers the sponsor has linked to this study.
- Other trials for Acute Asthma ExacerbationsStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 93 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Collaborators
- International Association of Noninvasive Mechanical Ventilation
- Responsible party
- Principal investigator, Sarah Mohammed Hashem Hamza Ahmed, Assiut University
- Investigators
- Antonio M. Esquinas, PhD, FCCP, Study director, International Council Respiratory Care, ICU, Hospital Morales Meseguer, Murcia, Spain.Mohammed M. Metwally, PhD, FCCR, Study director, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06652542
- Sponsor's protocol ID
- International Asthma Survey
- Acronym
- AERMIS
- Status last verified
- Aug 2026
- First submitted
- 18 Oct 2024
- Last updated
- 17 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention,2024. Updated May 2024.
Wang Z, Li Y, Gao Y, Fu Y, Lin J, Lei X, Zheng J, Jiang M. Global, regional, and national burden of asthma and its attributable risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Respir Res. 2023 Jun 23;24(1):169. doi: 10.1186/s12931-023-02475-6.
PubMed 37353829Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, Busby J, Jackson DJ, Pfeffer PE, Rhee CK, Cho YS, Canonica GW, Heffler E, Gibson PG, Hew M, Peters M, Harvey ES, Alacqua M, Zangrilli J, Bulathsinhala L, Carter VA, Chaudhry I, Eleangovan N, Hosseini N, Murray RB, Price DB. Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry. Chest. 2020 Apr;157(4):790-804. doi: 10.1016/j.chest.2019.10.053. Epub 2019 Nov 27.
PubMed 31785254Mohamed AZELA, Shaaban LH, Gad SF, Azeem EA, Gamal Elddin W. Acute severe asthma in emergency department: clinical characteristics, risk factors, and predictors for poor outcome. The Egyptian Journal of Bronchology. 2022;16(1).
Gayen S, Dachert S, Lashari BH, Gordon M, Desai P, Criner GJ, Cardet JC, Shenoy K. Critical Care Management of Severe Asthma Exacerbations. J Clin Med. 2024 Feb 1;13(3):859. doi: 10.3390/jcm13030859.
PubMed 38337552Aggarwal B, Al-Moamary M, Allehebi R, Alzaabi A, Al-Ahmad M, Amin M, Damayanti T, Van Tho N, Quyen PTL, Sriprasart T, Poachanukoon O, Yu-Lin AB, Ismail AI, Limpin MEB, Koenig S, Levy G, Phansalkar A, Rafih F, Silvey M, Miriams L, Milligan G. APPaRENT 3: Asthma Patients' and Physicians' Perspectives on the Burden and Management of Asthma in Seven Countries. Adv Ther. 2024 Aug;41(8):3089-3118. doi: 10.1007/s12325-024-02900-2. Epub 2024 Jun 14.
PubMed 38874879Garcia-Marcos L, Chiang CY, Asher MI, Marks GB, El Sony A, Masekela R, Bissell K, Ellwood E, Ellwood P, Pearce N, Strachan DP, Mortimer K, Morales E; Global Asthma Network Phase I Study Group. Asthma management and control in children, adolescents, and adults in 25 countries: a Global Asthma Network Phase I cross-sectional study. Lancet Glob Health. 2023 Feb;11(2):e218-e228. doi: 10.1016/S2214-109X(22)00506-X.
PubMed 36669806Ibrahim AO, Aremu SK, Afolabi BA, Ajani GO, Kolawole FT, Oguntoye O. Acute severe asthma and its predictors of mortality in rural Southwestern Nigeria: a-five year retrospective observational study. Chron Respir Dis. 2023 Jan-Dec;20:14799731221151183. doi: 10.1177/14799731221151183.
PubMed 36652901Selroos O, Kupczyk M, Kuna P, Lacwik P, Bousquet J, Brennan D, Palkonen S, Contreras J, FitzGerald M, Hedlin G, Johnston SL, Louis R, Metcalf L, Walker S, Moreno-Galdo A, Papadopoulos NG, Rosado-Pinto J, Powell P, Haahtela T. National and regional asthma programmes in Europe. Eur Respir Rev. 2015 Sep;24(137):474-83. doi: 10.1183/16000617.00008114.
PubMed 26324809Mortimer K, Reddel HK, Pitrez PM, Bateman ED. Asthma management in low and middle income countries: case for change. Eur Respir J. 2022 Sep 15;60(3):2103179. doi: 10.1183/13993003.03179-2021. Print 2022 Sep.
PubMed 35210321Talbot T, Roe T, Dushianthan A. Management of Acute Life-Threatening Asthma Exacerbations in the Intensive Care Unit. Applied Sciences. 2024;14(2)
Zeitouni MO, Al-Moamary MS, Coussa ML, Riachy M, Mahboub B, AlHuraish F, Zidan MH, Metwally MM, Aksu K, Yavuz E, Kalla IS, Chakaya J, Abdelmadjid S, Ghedira H. Challenges and recommendations for the management of asthma in the Middle East and Africa. Ann Thorac Med. 2022 Apr-Jun;17(2):71-80. doi: 10.4103/atm.atm_469_21. Epub 2022 Apr 19.
PubMed 35651897
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Asthma Exacerbations & Respiratory Management: An International Online Survey Endorsed by the International Association of Non-invasive Ventilation & International College of Experts
- ClinicalTrials.gov ID
- NCT06652542
- Acronym / sponsor ID
- AERMIS / International Asthma Survey
- Conditions
- Acute Asthma Exacerbations
- Keywords
- Asthma Exacerbations, International Survey, Attitudes and Preferences, International Association of Non-invasive Ventilation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 93 participants (actual)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Collaborators
- International Association of Noninvasive Mechanical Ventilation
- Study start
- 20 Feb 2024 (actual)
- Primary completion
- 20 Feb 2025 (actual)
- Study completion
- 20 Feb 2025 (actual)
- First posted
- 22 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Asthma is a chronic health condition that affects 300 million humans worldwide and is thought to cause around 1.000 deaths per day. It's estimated that asthma leads to a significant increase in disability adjusted life years (DALYs). Acute asthma exacerbations affect 25-56% of patients with asthma and represent 8% of intensive care unit (ICU) admissions. Acute asthma exacerbations continue to burden different health systems, particularly emergency units and intensive care units, despite vast advances in pharmacological treatment of asthma, development of evidence-based clinical practice guidelines to improve care of asthma.
This alarming situation indicates non-consensus regarding the best approach for managing acute exacerbations of asthma. Despite that variations in clinical practice regarding diagnosis, prevention, education, long-term management and symptom control of asthma have been thoroughly studied globally, less light has been shed on divergence of physicians' approaches when encountering asthmatic patients during acute exacerbations.
Detailed description
Aim of the Study:
Exploring the physicians' knowledge, attitude and current clinical, pharmacological and ventilatory management practices for acute asthma exacerbations.
Methodology:
Study Design:
The survey is intended to be a cross-sectional survey study.
Time Period:
February 2024-February 2025.
Study Settings:
Respondents are to be recruited by the authors, who are to distribute the online survey to targeted colleagues within the medical institutions the authors are affiliated to, and through different national and international scientific societies of common interest in pulmonology and critical care medicine. Individual physicians are free to distribute the online questionnaire form via electronic communication through the channels they deem most appropriate.
Target Respondents:
Physicians involved in the care of adult asthmatic patients (general practitioners, family medicine doctors, internists, pulmonologists, intensivists in different medical ICUs).
Development of the Questionnaire Questions:
First, a thorough revision of existing literature related to different aspects of management of asthma exacerbations was performed. A total of 45 articles published in national and international journals -including review articles, clinical trials, editorials, and meta-analyses-discussing diagnosis, severity assessment, pharmacological and ventilatory management, as well as outcomes of acute asthma exacerbations were examined to find points of variation in clinical practice, distinguish which approaches are evidence-based, and the magnitude and the pattern of deviation from clinical practice guidelines in different countries. Then, data to be explored were organized into seven domains:
Domain 1.: Respondents' characteristics:
This includes age, geographic region, specialty, years of experience, clinical position and academic degree (if present), affiliation, as well as the level of the health care facility through which a respondent provides care to patients presenting with acute asthma exacerbations.
Domain 2.: Diagnosis of acute asthma exacerbations:
Respondents are to report whether their reliance is wholly on clinical judgement or on tools provided by certain local or international practice guidelines when it comes to identifying asthma patients in acute exacerbations and deciding upon emergency room (ER) admission or ICU referral.
Domain 3.: Pharmacological Management of Acute Asthma Exacerbations:
This domain aims to measure the respondents' knowledge about different pharmacological therapies administrated during acute asthma exacerbations, their usual practice as governed by local policies and resources, as well as their individual preferences towards certain approaches, to detect gaps between knowledge and practice. Drugs including bronchodilators, systemic steroids, antibiotics, and anti-histaminic are to be inquired about regarding frequency of use, method of administration, prescribed doses, and ideal/preferred alternatives. Use of other drugs like magnesium sulphate, theophylline, epinephrine, inhaled anesthetics and intravenous ketamine is to be verified, and respondents are asked to report their knowledge about whether the use of any of these drugs is endorsed by any clinical practice guidelines they are aware of.
Domain 4.: Oxygen therapy during acute asthma exacerbations:
This domain screens the knowledge of the respondents about indications of oxygen administration during acute asthma exacerbations, explores their attitude towards the choice of oxygen delivery system. Familiarity of respondents with the settings of high-flow nasal cannula (HFNC), barriers towards its use, as well as physicians' preferences regarding HFNC are also explored.
Domain 5.: Non-invasive ventilation (NIV) in acute asthma exacerbations:
Access to NIV, frequency of its use, the available NIV devices, and the preferred NIV mode and interfaces by a respondent are inquired about. Respondents' knowledge of the physiological rationales behind using NIV, the appropriate settings of NIV for patients presenting with acute asthma exacerbations, and how to address the main problems arising in such patients are challenged. Knowledge, attitudes and respondents' preferences towards use of sedation during NIV in critically ill asthmatics, knowledge of the best approach to deliver nebulized drugs during NIV, understanding of NIV interference with nebulization therapy, as well as individual preferences regarding the method of delivery are all explored. Barriers to the use of NIV for acute asthma exacerbations, and potential complications associated with its application are also investigated.
Domain 6.: Invasive mechanical ventilation (IMV)in acute asthma exacerbations:
Respondents are inquired about frequency of application of IMV in acute asthma exacerbations, the units where IMV is provided, their knowledge about pathophysiology of severe asthma exacerbations, the appropriate mode and settings of MV, the role of sedation and neuromuscular blockade and the respondents' attitudes and preferences towards the use of these drugs and monitoring patients whilst administration of these drugs are explored. Adjustment of ventilatory settings prior to administration of nebulized drugs and frequency of complications during IMV of acute asthma exacerbations are inquired about as well.
Domain 7.: Outcomes of acute asthma exacerbations:
Respondents' knowledge about possible predictors of prognosis of patients presenting with asthma exacerbations is assessed.
Ethical Considerations:
Ethical Considerations:
The study being academically endorsed by "The International Association of Noninvasive Mechanical Ventilation", has been subjected to evaluation by the IANIV- Bioethics Committee for Clinical Research studies evaluation, Internal Code: EST: 87/24, and was granted approval. Also, the online questionnaire form includes a disclosure in its description that clarifies that the study does not collect personal identifiable or sensitive data of the contributors or patients' data and only include information and opinions about clinical practice related to Asthma treatments. Data, e.g. age, affiliation, practice-years, are only collected for analytic purposes and are strictly treated as confidential by the authors, who assure that data will not be shared or unlawfully used. A consent statement at the start of the questionnaire states a declaration of consent and that the respondent is a medical doctor who holds at least a graduate degree in medical science. Answering "yes" leads the respondent to the first domain, while answering "no" automatically leads the respondent to the end of the form to be submitted.
The online questionnaire form includes a consent statement at the start of the questionnaire that states a declaration of consent and that the respondent is a medical doctor who holds at least a graduate degree in medical science. Answering "yes" leads the respondent to the first domain, while answering "no" automatically leads the respondent to the end of the form to be submitted.
Data Storage and Confidentiality:
Contact information, i.e. e-mail address is set to be optional. Other personal information such as age, years of experience and affiliation are to be collected for the descriptive purposes and depiction of general characteristics of the respondents providing information but are not to be unlawfully shared or distributed. Access to such information is set to be exclusively restricted to the authors of the questionnaire form. After data analysis, results will be published -maintaining respondents' anonymity- and will be available upon request.
Management of Adverse Events:
Given the commitment of the authors to respondents' confidentiality, no adverse events are expected from this study.
Statistical Analysis:
A certified epidemiologist statistician is to help with statistical analysis. Descriptive statistics will be conducted as well as relevant inferential statistics.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 23 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Pulmonologists, internists, paediatricians, and intensivists at primary, secondary, or tertiary health care facility, from different countries and geographic territories, with varying years of experience and academic backgrounds
Key inclusion criteria (1 listed)
- All practicing physician who may encounter patients with asthma during their clinical practice are invited to participate.
Key exclusion criteria (1 listed)
- Non-practicing undergraduate medical students
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Physicians Knowledge & Attitudes: Diagnosis of Asthma Exacerbations
Time frame: Through study completion i.e. over an average of 1 year
A respondent chooses from multiple choices a statement that best describes their knowledge/attitudes regarding the criteria used for diagnosis of acute asthma exacerbations (prespecified criteria derived from clinical practice guidelines or local policies rather than clinical judgement) . The number of responding physician to each statement is to be recorded.
Physicians' Knowledge and Attitudes: Pharmacological Management
Time frame: Through study completion i.e. over an average of 1 year
A respondent chooses from multiple choices a statement that best describes their knowledge/attitudes regarding the use of different asthma medications (bronchodilators, steroids, sedatives, neuromuscular blockers). The number of responding physician to each statement is to be recorded.
Physicians Knowledge & Attitudes: Ventilatory Management
Time frame: Through study completion i.e. over an average of 1 year
A respondent chooses from multiple choices a statement that best describes their knowledge/attitudes regarding the frequency of use of different ventilatory support methods (oxygen therapy, high-velocity nasal insufflation (HVNI), noninvasive ventilation (NIV), invasive mechanical ventilation (IMV)) and the appropriate settings. Physicians' awareness about expected adverse events of each modality is tested. The number of responding physician to each statement is to be recorded.
1 secondary outcome
Physicians' Knowledge: Prognosis of Acute Asthma Exacerbations
Time frame: Through study completion i.e. over an average of 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2026.
- BackgroundGlobal Initiative for Asthma. Global Strategy for Asthma Management and Prevention,2024. Updated May 2024.
- Background: PubMed 37353829Wang Z, Li Y, Gao Y, Fu Y, Lin J, Lei X, Zheng J, Jiang M. Global, regional, and national burden of asthma and its attributable risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Respir Res. 2023 Jun 23;24(1):169. doi: 10.1186/s12931-023-02475-6.
- Background: PubMed 31785254Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, Busby J, Jackson DJ, Pfeffer PE, Rhee CK, Cho YS, Canonica GW, Heffler E, Gibson PG, Hew M, Peters M, Harvey ES, Alacqua M, Zangrilli J, Bulathsinhala L, Carter VA, Chaudhry I, Eleangovan N, Hosseini N, Murray RB, Price DB. Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry. Chest. 2020 Apr;157(4):790-804. doi: 10.1016/j.chest.2019.10.053. Epub 2019 Nov 27.
- BackgroundMohamed AZELA, Shaaban LH, Gad SF, Azeem EA, Gamal Elddin W. Acute severe asthma in emergency department: clinical characteristics, risk factors, and predictors for poor outcome. The Egyptian Journal of Bronchology. 2022;16(1).
- Background: PubMed 38337552Gayen S, Dachert S, Lashari BH, Gordon M, Desai P, Criner GJ, Cardet JC, Shenoy K. Critical Care Management of Severe Asthma Exacerbations. J Clin Med. 2024 Feb 1;13(3):859. doi: 10.3390/jcm13030859.
- Background: PubMed 38874879Aggarwal B, Al-Moamary M, Allehebi R, Alzaabi A, Al-Ahmad M, Amin M, Damayanti T, Van Tho N, Quyen PTL, Sriprasart T, Poachanukoon O, Yu-Lin AB, Ismail AI, Limpin MEB, Koenig S, Levy G, Phansalkar A, Rafih F, Silvey M, Miriams L, Milligan G. APPaRENT 3: Asthma Patients' and Physicians' Perspectives on the Burden and Management of Asthma in Seven Countries. Adv Ther. 2024 Aug;41(8):3089-3118. doi: 10.1007/s12325-024-02900-2. Epub 2024 Jun 14.
- Background: PubMed 36669806Garcia-Marcos L, Chiang CY, Asher MI, Marks GB, El Sony A, Masekela R, Bissell K, Ellwood E, Ellwood P, Pearce N, Strachan DP, Mortimer K, Morales E; Global Asthma Network Phase I Study Group. Asthma management and control in children, adolescents, and adults in 25 countries: a Global Asthma Network Phase I cross-sectional study. Lancet Glob Health. 2023 Feb;11(2):e218-e228. doi: 10.1016/S2214-109X(22)00506-X.
- Background: PubMed 36652901Ibrahim AO, Aremu SK, Afolabi BA, Ajani GO, Kolawole FT, Oguntoye O. Acute severe asthma and its predictors of mortality in rural Southwestern Nigeria: a-five year retrospective observational study. Chron Respir Dis. 2023 Jan-Dec;20:14799731221151183. doi: 10.1177/14799731221151183.
- Background: PubMed 26324809Selroos O, Kupczyk M, Kuna P, Lacwik P, Bousquet J, Brennan D, Palkonen S, Contreras J, FitzGerald M, Hedlin G, Johnston SL, Louis R, Metcalf L, Walker S, Moreno-Galdo A, Papadopoulos NG, Rosado-Pinto J, Powell P, Haahtela T. National and regional asthma programmes in Europe. Eur Respir Rev. 2015 Sep;24(137):474-83. doi: 10.1183/16000617.00008114.
- Background: PubMed 35210321Mortimer K, Reddel HK, Pitrez PM, Bateman ED. Asthma management in low and middle income countries: case for change. Eur Respir J. 2022 Sep 15;60(3):2103179. doi: 10.1183/13993003.03179-2021. Print 2022 Sep.
- BackgroundTalbot T, Roe T, Dushianthan A. Management of Acute Life-Threatening Asthma Exacerbations in the Intensive Care Unit. Applied Sciences. 2024;14(2)
- Background: PubMed 35651897Zeitouni MO, Al-Moamary MS, Coussa ML, Riachy M, Mahboub B, AlHuraish F, Zidan MH, Metwally MM, Aksu K, Yavuz E, Kalla IS, Chakaya J, Abdelmadjid S, Ghedira H. Challenges and recommendations for the management of asthma in the Middle East and Africa. Ann Thorac Med. 2022 Apr-Jun;17(2):71-80. doi: 10.4103/atm.atm_469_21. Epub 2022 Apr 19.
- The online questionnaire form distributed for recruiting respondentsLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Acute Asthma Exacerbations
RecruitingPhase 2
Rademikibart IV for Acute Asthma and COPD Exacerbation
Asthma Acute, COPD Exacerbation Acute
Active, not recruitingPhase 3
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Asthma
Not yet recruiting
Bilevel Positive Airway Pressure (BPAP) for Severe Asthma
Pediatric Asthma, Acute Asthma
Recruiting
Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects
Asthma Acute
RecruitingPhase 2
Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations
Asthma Acute, Asthma Attack
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Antonio M. Esquinas, PhD, FCCP study director
International Council Respiratory Care, ICU, Hospital Morales Meseguer, Murcia, Spain.
Mohammed M. Metwally, PhD, FCCR study director
Assiut University
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Asthma Exacerbations, run by Assiut University at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Egypt, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Physicians Knowledge & Attitudes: Diagnosis of Asthma Exacerbations (time frame: Through study completion i.e. over an average of 1 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06652542, which also lists 12 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2026.